In the present study, we showed that the OS was significantly longer in patients who underwent surgery for primary site with de novo stage IV BC, especially in patients with HR + and/or HER2 + BC, than in those who did not undergo surgery. The gene discussed is ERBB2; the disease is breast cancer.